Drug Profile
Research programme: oral monoclonal antibodies - AIMM Therapeutics/Cosmo Pharmaceuticals
Latest Information Update: 20 Dec 2023
Price :
$50
*
At a glance
- Originator AIMM Therapeutics; Cosmo Pharmaceuticals
- Class Monoclonal antibodies; Monoclonal antibody diagnostics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Colorectal cancer; Gastrointestinal disorders
Most Recent Events
- 05 Feb 2021 AIMM Therapeutics has been acquired and merged into Kling Biotherapeutics
- 16 Jul 2016 No recent reports of development identified for research development in Colorectal-cancer in Europe (PO, Controlled release)
- 16 Jul 2016 No recent reports of development identified for research development in Colorectal-cancer(Diagnosis) in Europe (PO, Controlled release)